Emugrobart — Safety, Research, Risks & Legal Status

Not medical advice. Emugrobart is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	GYM-329; RG6237; RG-70240
Category	Peptide (research chemical)
Drug class	Humanized monoclonal antibody, IgG1κ isotype; anti-pro/latent myostatin (GDF-8)
Developer	Chugai Pharmaceutical Co., Ltd. (Roche Group), in collaboration with Genentech/Roche
Platform technology	Sweeping antibody: pH-dependent antigen release + FcγRIIb-mediated endocytosis + FcRn recycling enables catalytic target clearance
Discontinued indications	Spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD) - March 2026, after Phase II/III efficacy failures
Active investigation	Obesity (GYMINDA trial, in combination with tirzepatide) and type 2 diabetes; Phase I/II results expected late 2026
Human efficacy status	No positive efficacy data published in any human indication as of mid-2026
US legal status	Investigational agent; never approved by the FDA for any indication. No NDA or approved IND for human use outside of clinical trials. Clinical development was discontinued in March 2026 for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD) after Phase II/III efficacy failures. Active Phase I/II trials in obesity and type 2 diabetes remain ongoing as of mid-2026. Not available for human use outside of sponsored clinical trials. Not a dietary supplement. Cannot be legally marketed or sold for human consumption in the United States.

What is Emugrobart?

Emugrobart is a humanized monoclonal antibody (IgG1κ isotype) developed by Chugai Pharmaceutical (a Roche Group subsidiary) in collaboration with Roche/Genentech. It targets pro-myostatin and latent myostatin (GDF-8), the precursor forms of a potent negative regulator of skeletal muscle mass. Emugrobart was engineered using proprietary "sweeping antibody" technology designed to clear myostatin from both muscle tissue and plasma at substantially lower doses than conventional anti-myostatin biologics. Development for neuromuscular indications (SMA, FSHD) was halted in March 2026 after Phase II/III trials failed to demonstrate functional benefit. Ongoing Phase I/II trials in obesity and type 2 diabetes were continuing as of mid-2026.

How it works

Emugrobart employs a pH-dependent, Fc-engineered "sweeping antibody" mechanism. It binds latent and pro-myostatin at physiological pH (approximately 7.4), blocking proteolytic cleavage to active mature myostatin. The antibody-antigen complex is internalized via receptor-mediated endocytosis through FcγRIIb-expressing cells. In the acidic endosomal compartment (approximately pH 5.8), the pH-sensitive antibody releases its antigen; the free myostatin is shuttled to lysosomes for degradation, while the antibody is recycled to the cell surface via the neonatal Fc receptor (FcRn) for further rounds of target capture. This iterative capture-and-lysosomal-degradation cycle is designed to achieve systemic myostatin depletion at roughly 10-fold lower molar doses compared to conventional stoichiometric anti-myostatin agents such as landogrozumab or domagrozumab.

Background & history

Emugrobart originated from Chugai Pharmaceutical's engineered-antibody platform, with early preclinical characterization published around 2020-2021 using surrogate molecules (GYM-mFc in mice, GYM-cyFc in non-human primates). The compound entered clinical development under the codenames GYM-329 and RG6237. Phase II trials in FSHD (MANOEUVRE; NCT05548556) and a Phase II/III trial in SMA in combination with risdiplam (MANATEE; NCT05115110) were initiated with considerable interest given the molecule's mechanistic novelty and strong preclinical profile. In March 2026, Roche and Chugai announced discontinuation of both neuromuscular programs following efficacy misses - the SMA combination cohort did not demonstrate consistent or robust functional improvements over risdiplam alone, and the FSHD trial similarly failed. Despite these setbacks, the programs in obesity (GYMINDA trial; NCT06965413, in combination with tirzepatide) and type 2 diabetes (NCT07137585) remained active as of mid-2026, with primary completion expected in late 2026. A regulatory filing pathway in metabolic disease was internally projected for 2028 at the earliest, contingent on positive trial outcomes.

What the research says

Human efficacy data: None published demonstrating clinical benefit. Phase II in FSHD (MANOEUVRE) failed. Phase II/III Part 1 in SMA (MANATEE) failed to show functional improvement versus risdiplam alone. Both programs were discontinued March 2026. Ongoing Phase II in obesity (GYMINDA) combines emugrobart with tirzepatide and is assessing changes in weight, lean mass, and muscle volume; no results available as of mid-2026. A Phase I trial in type 2 diabetes and obesity is also ongoing with no released data. Favorable safety was observed across completed trials - no serious adverse events, no treatment withdrawals attributable to the drug, and no identified safety signals. Preclinical data (animal only): In mdx (DMD-model) mice, statistically significant grip strength improvements were observed at low and high doses. In aged sarcopenic mice (79-week), grip strength recovery approached levels seen in young controls. Hindlimb suspension atrophy models demonstrated near-complete suppression of muscle mass loss. In cynomolgus monkeys, increases in muscle cross-sectional area on MRI, enhanced bodyweight gain, and rapid plasma myostatin reduction were observed without detectable toxicological signals. These results represent the strongest evidence base for the compound; translation to human benefit was not established in neuromuscular indications. The failure in SMA and FSHD despite confirmed target engagement (myostatin reduction) raises unresolved mechanistic questions about whether myostatin inhibition alone is sufficient in these conditions, or whether patient selection, dosing timing, or indication choice contributed to failure.

Reported effects

Preclinical (animal): substantial grip strength improvement in dystrophic and atrophic mouse models
Preclinical (animal): muscle mass preservation in hindlimb suspension atrophy
Preclinical (animal): increased muscle cross-sectional area in non-human primates
Plasma myostatin reduction (sweeping function confirmed in human trials, though functional efficacy was not demonstrated)
No established efficacy in humans for any indication as of mid-2026
Ongoing investigation for effects on lean mass and weight loss in combination with tirzepatide (obesity; no results released)
Ongoing investigation for insulin sensitivity and body composition in type 2 diabetes (no results released)

Dosing & administration (informational)

Published clinical trial protocols have not been fully disclosed in the public literature. Animal studies used low and high dose bracketing with surrogate molecules; the 10-fold dose reduction versus conventional anti-myostatin agents is a mechanistic claim from preclinical comparisons. No human dosing information sufficient to constitute a reference range is available in the public domain. This entry does not provide dosing guidance. Any clinical administration occurs exclusively within a licensed trial under physician supervision. Consult a clinician or the relevant trial site for any questions about participation.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Favorable safety profile in all completed Phase I and Phase II trials to date
No serious adverse events reported in SMA or FSHD trials
No treatment discontinuations due to safety concerns in completed trials
No identified safety signals across available trial data
Mechanistically, myostatin inhibition in healthy humans has not produced major adverse musculoskeletal effects in similar compound classes, though long-term data are limited
No approved human safety label exists; the compound has not been reviewed by FDA for marketing authorization
Data in obesity and type 2 diabetes trials remain unreleased; extrapolating safety to metabolic populations or long-term use is premature

Drug & supplement interactions

N
o
f
o
r
m
a
l
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
h
a
v
e
b
e
e
n
p
u
b
l
i
s
h
e
d
.
T
h
e
M
A
N
A
T
E
E
t
r
i
a
l
e
v
a
l
u
a
t
e
d
e
m
u
g
r
o
b
a
r
t
i
n
c
o
m
b
i
n
a
t
i
o
n
w
i
t
h
r
i
s
d
i
p
l
a
m
(
a
n
S
M
N
2
s
p
l
i
c
i
n
g
m
o
d
i
f
i
e
r
)
w
i
t
h
o
u
t
i
d
e
n
t
i
f
i
e
d
s
a
f
e
t
y
i
n
t
e
r
a
c
t
i
o
n
s
,
t
h
o
u
g
h
n
o
f
u
n
c
t
i
o
n
a
l
b
e
n
e
f
i
t
w
a
s
o
b
s
e
r
v
e
d
.
T
h
e
G
Y
M
I
N
D
A
t
r
i
a
l
p
a
i
r
s
e
m
u
g
r
o
b
a
r
t
w
i
t
h
t
i
r
z
e
p
a
t
i
d
e
(
G
I
P
/
G
L
P
-
1
d
u
a
l
a
g
o
n
i
s
t
)
;
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
a
r
e
n
o
t
y
e
t
a
v
a
i
l
a
b
l
e
.
A
s
a
m
o
n
o
c
l
o
n
a
l
a
n
t
i
b
o
d
y
,
e
m
u
g
r
o
b
a
r
t
i
s
u
n
l
i
k
e
l
y
t
o
i
n
v
o
l
v
e
c
y
t
o
c
h
r
o
m
e
P
4
5
0
m
e
t
a
b
o
l
i
s
m
,
b
u
t
e
f
f
e
c
t
s
o
n
m
u
s
c
l
e
m
a
s
s
o
r
i
n
s
u
l
i
n
s
e
n
s
i
t
i
v
i
t
y
c
o
u
l
d
t
h
e
o
r
e
t
i
c
a
l
l
y
i
n
t
e
r
a
c
t
w
i
t
h
i
n
s
u
l
i
n
s
e
c
r
e
t
a
g
o
g
u
e
s
,
a
n
a
b
o
l
i
c
a
g
e
n
t
s
,
o
r
o
t
h
e
r
b
o
d
y
-
c
o
m
p
o
s
i
t
i
o
n
-
m
o
d
i
f
y
i
n
g
t
h
e
r
a
p
i
e
s
.
N
o
i
n
f
o
r
m
a
t
i
o
n
i
s
a
v
a
i
l
a
b
l
e
t
o
c
h
a
r
a
c
t
e
r
i
z
e
i
n
t
e
r
a
c
t
i
o
n
s
i
n
a
n
o
n
-
t
r
i
a
l
c
o
n
t
e
x
t
.

Who should avoid it

Use outside of a licensed clinical trial - no approved indication exists
Sourcing from non-pharmaceutical suppliers - no legitimate consumer supply exists for this biologic
Assuming preclinical muscle-building results translate to human benefit - Phase II/III neuromuscular trials failed
Extrapolating SMA/FSHD trial safety or efficacy data to other populations without restriction
Combining with other myostatin-pathway agents or anabolics without clinical oversight
Inferring metabolic or obesity benefit prior to release of GYMINDA and Phase I diabetes trial results

How it is commonly combined

No evidence base for stacking or combination use outside of clinical trials. The GYMINDA trial is evaluating combination with tirzepatide in obesity; this is a supervised, protocol-driven pairing, not an endorsement of unsupervised co-administration. Combining anti-myostatin agents with anabolic steroids, SARMs, peptide secretagogues, or other body-composition agents has no published safety or efficacy data for emugrobart specifically and carries unknown risks.

Legal & regulatory. Investigational agent; never approved by the FDA for any indication. No NDA or approved IND for human use outside of clinical trials. Clinical development was discontinued in March 2026 for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD) after Phase II/III efficacy failures. Active Phase I/II trials in obesity and type 2 diabetes remain ongoing as of mid-2026. Not available for human use outside of sponsored clinical trials. Not a dietary supplement. Cannot be legally marketed or sold for human consumption in the United States.

Quality & harm reduction

E
m
u
g
r
o
b
a
r
t
i
s
a
b
i
o
l
o
g
i
c
(
m
o
n
o
c
l
o
n
a
l
a
n
t
i
b
o
d
y
)
p
r
o
d
u
c
e
d
u
n
d
e
r
p
h
a
r
m
a
c
e
u
t
i
c
a
l
G
M
P
b
y
C
h
u
g
a
i
/
R
o
c
h
e
f
o
r
c
l
i
n
i
c
a
l
t
r
i
a
l
u
s
e
.
I
t
i
s
n
o
t
c
o
m
m
e
r
c
i
a
l
l
y
a
v
a
i
l
a
b
l
e
.
T
h
e
r
e
i
s
n
o
l
e
g
i
t
i
m
a
t
e
c
o
n
s
u
m
e
r
o
r
r
e
s
e
a
r
c
h
-
c
h
e
m
i
c
a
l
s
u
p
p
l
y
c
h
a
i
n
f
o
r
t
h
i
s
c
o
m
p
o
u
n
d
.
A
n
y
m
a
t
e
r
i
a
l
s
o
l
d
o
u
t
s
i
d
e
o
f
a
l
i
c
e
n
s
e
d
c
l
i
n
i
c
a
l
t
r
i
a
l
c
o
n
t
e
x
t
c
a
n
n
o
t
b
e
v
e
r
i
f
i
e
d
f
o
r
i
d
e
n
t
i
t
y
,
p
u
r
i
t
y
,
o
r
s
t
e
r
i
l
i
t
y
.
M
o
n
o
c
l
o
n
a
l
a
n
t
i
b
o
d
i
e
s
r
e
q
u
i
r
e
c
o
l
d
-
c
h
a
i
n
h
a
n
d
l
i
n
g
a
n
d
s
t
e
r
i
l
e
f
o
r
m
u
l
a
t
i
o
n
;
t
h
e
y
c
a
n
n
o
t
b
e
r
e
l
i
a
b
l
y
r
e
p
l
i
c
a
t
e
d
o
u
t
s
i
d
e
a
p
h
a
r
m
a
c
e
u
t
i
c
a
l
m
a
n
u
f
a
c
t
u
r
i
n
g
e
n
v
i
r
o
n
m
e
n
t
.

Safer, legal alternative we recommend

Creatine Supreme. For supporting muscle mass and strength, creatine monohydrate is the most evidence-backed legal option, with decades of safety data - ours ships from the Peptropix line.

See our recommended pick

Find Emugrobart →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Why did emugrobart fail in SMA and FSHD if the preclinical data looked strong?

The reasons are not fully established in the public literature. Target engagement (myostatin reduction in plasma) was confirmed in trials, suggesting the sweeping mechanism worked at the pharmacological level. The failure raises questions that the field has not yet resolved: whether myostatin inhibition alone is sufficient to drive functional improvement in these conditions, whether the patient populations or disease stages studied were suboptimal, or whether dosing duration was inadequate. Roche and Chugai have not published detailed mechanistic analyses of the failures as of mid-2026.

Is emugrobart being abandoned entirely, or is development continuing?

Development was discontinued only for SMA and FSHD. As of mid-2026, Phase II (GYMINDA) and Phase I trials in obesity and type 2 diabetes remain active. Roche's internal projection for a potential regulatory filing in metabolic indications was 2028 at the earliest, contingent on positive results from those ongoing trials.

Where can I get emugrobart?

Emugrobart is not commercially available anywhere. It exists only as an investigational biologic manufactured under pharmaceutical GMP for use within licensed clinical trials. There is no legitimate consumer, compounding, or research-chemical source. Any material sold outside a clinical trial cannot be authenticated and would carry unknown risks of contamination, incorrect identity, or improper formulation.

What is the sweeping antibody technology and why does it matter?

Conventional monoclonal antibodies bind their target in a one-to-one stoichiometric manner - one antibody molecule neutralizes one antigen molecule before both are degraded. Sweeping antibody technology, as implemented in emugrobart, engineers pH-dependent antigen binding: the antibody releases its target in the acidic endosome, the target is degraded, and the antibody is recycled to the surface for repeated target capture cycles. The claimed result is roughly 10-fold greater molar efficiency compared to conventional anti-myostatin antibodies like landogrozumab. This is a pharmacological engineering advance, but it does not guarantee clinical efficacy, as the SMA and FSHD results demonstrated.

Is there any evidence emugrobart builds muscle in humans?

No. No published human efficacy data demonstrate muscle growth or functional improvement. The neuromuscular trials (SMA and FSHD) failed on functional endpoints. Ongoing metabolic trials are assessing lean mass and muscle volume changes in obesity and diabetes contexts, but those results are not yet available. All muscle-building evidence comes from animal models.

What is the safety profile?

In completed Phase I and Phase II trials (SMA and FSHD programs), emugrobart was well tolerated with no serious adverse events, no treatment discontinuations due to safety, and no identified safety signals. However, the compound has never been reviewed or approved by the FDA, no long-term safety data exist in humans, and safety in metabolic populations has not been published. The absence of observed adverse events in short-duration trials is reassuring context but does not constitute a complete characterization of risk.

References & further reading

PubMed: "GYM329 myostatin sweeping antibody" or "emugrobart clinical trial" or "RG6237 myostatin"
ClinicalTrials.gov: NCT05548556 (MANOEUVRE - FSHD Phase II)
ClinicalTrials.gov: NCT05115110 (MANATEE - SMA Phase II/III)
ClinicalTrials.gov: NCT06965413 (GYMINDA - obesity Phase II, tirzepatide combination)
ClinicalTrials.gov: NCT07137585 (Phase I - type 2 diabetes and obesity)